Focused
Concentrating on areas where a targeted local approach could meaningfully change the treatment paradigm.
Precision science. Focused delivery. Meaningful impact.
Advancing a new approach to ocular oncology.
Contact UsAbout Lumeriq
Built around a clear idea: deliver therapy where it matters most.
Lumeriq Bio Inc. is a biotechnology company developing innovative, localized therapeutic approaches for serious ocular cancers, beginning with Retinoblastoma.
Pragmatic
Building from known therapeutic agents and translational insight to create a disciplined development path.
Patient-centered
Keeping the clinical need of children and families facing rare ocular cancers at the center of development.
Starting with Retinoblastoma
Lumeriq Bio is developing a novel localized therapeutic approach for Retinoblastoma, a rare pediatric ocular cancer with significant unmet need. Our program is designed around precision, thoughtful clinical translation, and a disciplined development strategy focused on improving treatment options for patients and families.
*Investigational program. No product has been approved by the U.S. Food and Drug Administration.
Interested in learning more about Lumeriq Bio?
We welcome inquiries from potential partners, investors, clinicians, and others interested in our mission to advance new approaches in ocular oncology.
